A previous phase II trial with nivolumab in melanoma cases has shown that IFN‐γ, IL‐6, and IL‐10 levels in the responders were significantly increased when compared to non-responders (p < 0.0001, p = 0.0007, and p < 0.0001, respectively). This evidence concerns the gene IFNG and melanoma.